

**The Royal Marsden NHS Foundation Trust**  
**Drug & Therapeutic Committee minutes**  
**29<sup>th</sup> January 2020**

**Present:** Consultant Breast and AOS (chair)  
Drug Resource Manager (secretary)  
Consultant Palliative Medicine  
Consultant Pharmacist  
Chief Pharmacist  
MI and palliative care specialist pharmacist  
Chemotherapy Nurse Consultant  
Consultant Medical Oncology – GI & AOS  
Consultant Microbiologist  
Pharmacy Administrator (minute taking)

**In attendance:**

**1. Minutes of the December meeting**

- a. Minutes – approved.

**2. Conflict of Interest**

No conflicts raised.

**3. NICE Guidance update**

1. TA621: Osimertinib for untreated EGFR+ve NSCLC
2. TA620: Olaparib for maintenance treatment of relapsed platinum sensitive ovarian, fallopian & peritoneal ca.
3. TA619: Palbociclib & fulvestrant in HR+ve, HER2-ve Breast ca.  
Relevant clinical leads made aware of the guidance.

**4. One off drug use requests**

1. Nivolumab (via CUP) in mismatch repair deficient oesophageal adenocarcinoma.
2. Eribulin (via CUP) in unresectable liposarcoma following standard treatment.
3. CAPOC regimen in recurrent carcinoma.
4. Abemaciclib in metastatic Breast ca. post palbociclib.
5. Olaparib (via CUP) in relapsed platinum sensitive ovarian ca. with BRCA mutation.
6. Lorlatinib as per MA – full proposal to come to next meeting.

All requests approved.

**5. Brincidofovir (via compassionate supply). Presented by the Haematology unit.**

Proposed for use Treatment of Adenovirus in adults and paediatric patients with renal impairment where Cidofovir is considered contraindicated or who have progressive adenoviraemia despite adequate treatment with Cidofovir in line with the criteria of the compassionate use program.

**Action:**

Approved.

**6. Ameluz (5-aminolevulinic acid hydrochloride) in actinic keratosis. Presented by Skin & Melanoma unit**

Proposed for use in treatment of actinic keratosis of mild to moderate severity on the face and scalp (Olsen grade 1 to 2) and of field cancerization in adults for superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment.

**Action:**  
Approved.

**7. IVIg annual report. Presented by the Pharmacy.**

The report showed that the internal and external approval processes were being adhered to at the trust. Patient numbers were similar to the previous year however expenditure has gone down slightly, this is hopefully an indication of the more stringent review processes in view of the development of the Sub Regional Immunoglobulin Assessment Panel.

**Action:**  
n/a.

**8. PGD: Lorazepam (SL) in cold related dyshaesia. Presented by Nursing.**

Developed in follow up to an action from the December meeting.

**Action:**  
Approved.

**9. Osteo Necrosis of the Jaw trust guidance review. Presented by IV therapies Nursing.**

New guidance has been published by a working party on behalf of UK Chemotherapy Board.

**Action:**  
To be taken to Quality Assurance & Chemotherapy for further review and implementation at the trust.

**10. AOB**

**Date of the Next Meeting:**

Thursday 20<sup>th</sup> of February (pm), 15:00 – 17:00

Minutes Approved	DTC chair: Tuesday 28 <sup>th</sup> April 2020
------------------	--

Date of next meeting 20 <sup>th</sup> February 2020.
--